Zacks: Analysts Anticipate AveXis, Inc. (NASDAQ:AVXS) Will Announce Earnings of -$0.95 Per Share

Analysts expect that AveXis, Inc. (NASDAQ:AVXS) will report earnings of ($0.95) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for AveXis’ earnings, with the highest EPS estimate coming in at ($0.79) and the lowest estimate coming in at ($1.10). AveXis posted earnings of ($0.68) per share in the same quarter last year, which indicates a negative year over year growth rate of 39.7%. The firm is expected to announce its next earnings report on Thursday, August 10th.

On average, analysts expect that AveXis will report full year earnings of ($4.42) per share for the current financial year, with EPS estimates ranging from ($5.61) to ($3.31). For the next year, analysts expect that the company will post earnings of ($4.05) per share, with EPS estimates ranging from ($5.32) to ($3.00). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow AveXis.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, May 11th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.13. During the same quarter last year, the firm posted ($1.24) earnings per share.

A number of equities research analysts have recently issued reports on the company. Sanford C. Bernstein assumed coverage on AveXis in a research report on Thursday, July 27th. They issued an “outperform” rating and a $108.00 price target for the company. Zacks Investment Research upgraded AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Jefferies Group LLC restated a “buy” rating on shares of AveXis in a research report on Wednesday, June 28th. Chardan Capital set a $103.00 price target on AveXis and gave the company a “buy” rating in a research report on Sunday, June 18th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $95.00 price target on shares of AveXis in a research report on Friday, June 16th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. AveXis has an average rating of “Buy” and a consensus price target of $90.89.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Rincon Hill News and is the sole property of of Rincon Hill News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://rinconhillneighbors.org/2017/08/19/zacks-analysts-anticipate-avexis-inc-nasdaqavxs-will-announce-earnings-of-0-95-per-share-updated-updated.html.

Shares of AveXis (AVXS) traded down 2.20% during trading on Thursday, hitting $90.61. The stock had a trading volume of 295,409 shares. The firm’s 50-day moving average is $80.27 and its 200 day moving average is $71.62. The firm’s market cap is $2.52 billion. AveXis has a 52-week low of $31.55 and a 52-week high of $94.59.

In related news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $81.88, for a total value of $145,746.40. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at $145,746.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 18.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of AVXS. BlackRock Inc. raised its position in shares of AveXis by 3,055.6% in the first quarter. BlackRock Inc. now owns 1,708,386 shares of the company’s stock valued at $129,888,000 after buying an additional 1,654,248 shares during the last quarter. State Street Corp raised its position in shares of AveXis by 619.2% in the fourth quarter. State Street Corp now owns 532,312 shares of the company’s stock valued at $25,408,000 after buying an additional 458,295 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of AveXis by 569.9% in the first quarter. Goldman Sachs Group Inc. now owns 227,961 shares of the company’s stock valued at $17,332,000 after buying an additional 193,934 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of AveXis by 32.8% in the first quarter. Point72 Asset Management L.P. now owns 717,514 shares of the company’s stock valued at $54,553,000 after buying an additional 177,114 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of AveXis by 11.7% in the first quarter. Vanguard Group Inc. now owns 1,194,809 shares of the company’s stock valued at $90,841,000 after buying an additional 124,750 shares during the last quarter. Institutional investors own 90.51% of the company’s stock.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get a free copy of the Zacks research report on AveXis (AVXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.